Justin Ho


Dr. Justin Ho is a Principal in the Life Sciences Practice. He is an experienced consultant in legal matters involving intellectual property, antitrust, and other commercial disputes concerning both liability and damages issues.

Dr. Ho has worked on matters involving a range of products, including biologics, small-molecule drugs, and medical devices. He has built substantial expertise in the business and regulatory considerations underlying drug and medical device development that complement his experience in economic analyses. For nearly a decade, he has been advising clients on disputes regarding efforts in drug development (license disputes and contract breach), antitrust matters (market definition and damages in reverse-payment settlements, and product tying), intellectual property disputes (evaluation of commercial success in ANDA litigation, reasonable royalty, and lost profit analyses), pricing (price fixing and welfare analyses), and product labeling matters (including both consumer and pharmaceutical product claims).

Dr. Ho’s doctoral work focused on industrial organization and the economic and strategic evaluation of firm behavior and contracting. His work has been published in the American Economic Review and the Journal of Industrial Economics.

Selected Engagements

  • 01
    AAA dispute involving the scope and breadth of exclusivity of a development deal for monoclonal antibodies
    In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two pharmaceutical companies, CRA...
    View engagement
  • 02
    CRA experts testify in civil antitrust trial involving alleged tying of PICC lines and location devices
    On October 3, 2022, CRA experts testified on behalf of C.R. Bard in AngioDynamics, Inc. v. C.R. Bard, Inc. et al. in the Northern District of New York....
    View engagement
  • 03
    Evaluation of extended-release pain medication
    CRA consultants supported Plaintiff in a patent litigation regarding an extended-release formulation of an anti-pain medication. CRA assessed the commercial...
    View engagement